TABLE 2 .
Primary articles describing studies that utilized Lactobacillus to express bacterial antigensa
Pathogen |
Lactobacillus species |
Antigen(s) expressed |
Expression | Result(s) | Intended host(s) |
Reference |
---|---|---|---|---|---|---|
Bacillus anthracis | L. gasseri | PA | Unknown | Serum IgG, mucosal IgA, T cell response | Human, animal |
71 |
Bacillus anthracis | L. gasseri | PA | Unknown | Neutr. Ab, T cell response, challenge | Human | 70 |
Bacillus anthracis | L. acidophilus | PA | Surface | Neutr. Ab, mucosal IgA, challenge | Human | 69 |
Bacillus anthracis | L. casei | PA | Surface, intracell., secreted |
Serum IgG | Human | 68 |
Bacillus anthracis | L. acidophilus | PA | Surface | Stability | Human | 114 |
Borrelia burgdorferi | L. plantarum | OspA | Surface | Serum IgG, mucosal IgA | Human | 83 |
Borrelia burgdorferi | L. plantarum | OspA | Unknown | Serum IgG, mucosal IgA, challenge | Human | 82 |
Bordetella pertussis | L. casei | FHA | Intracell. | Serum IgG | Human | 115 |
Clostridium botulinum | L. acidophilus | BoNT/A-Hc | Surface | Stability | Human | 114 |
Clostridium perfringens | L. casei | ε-Toxoid | Surface | Serum IgG, serum IgA, intestinal IgA, IFN-γ, challenge |
Human, animal |
86 |
Clostridium perfringens | L. casei | α-, β1-, β2-, ε-toxoids |
Unknown | Serum IgG, fecal IgA, nasal IgA, IFN-γ/IL-4, T cell response, challenge |
Human, animal |
116 |
Clostridium perfringens | L. casei | β-Toxoid | Surface, intracell. |
Serum IgG, serum IgA, intestinal IgA, IFN-γ, challenge |
Human, animal |
117 |
Clostridium perfringens | L. casei | α-Toxoid | Surface | Serum IgG, mucosal IgA, challenge | Human, animal |
118 |
Chlamydia psittaci | L. fermentum | OmpA | Surface | Stability | Animal | 97 |
Clostridium tetani | L. casei | TTFC | Surface, intracell., secreted |
Serum IgG | Human | 119 |
Clostridium tetani | L. plantarum | TTFC | Intracell. | Serum IgG, mucosal IgA | Human | 120 |
Clostridium tetani | L. plantarum | TTFC | Intracell. | Serum IgG | Human | 121 |
Clostridium tetani | L. johnsonii | TTFC | Surface | Serum IgG, mucosal IgA | Human | 122 |
Clostridium tetani | L. plantarum | TTFC | Intracell., secreted, surface |
Serum IgG, mucosal IgA | Human | 123 |
Clostridium tetani | L. plantarum | TTFC | Intracell. | Serum IgG, mucosal IgA, T cell response, challenge |
Human | 124 |
Clostridium tetani |
L. plantarum, L. casei |
TTFC | Intracell., surface |
Serum IgG, mucosal IgA, T cell response | Human | 125 |
Chlamydia trachomatis |
L. plantarum, L. fermentum |
VD4 | Surface | Stability | Human | 126 |
Chlamydia trachomatis | L. plantarum | Hirep2 | Surface | Serum IgG, serum IgA, mucosal IgA, IFN-γ | Human | 90 |
Escherichia coli (EHEC O157:H7) |
L. acidophilus | EspA, Tir |
Secreted | Serum IgG, mucosal sIgA, IFN-γ, IL-4, IL-10, challenge |
Human | 127 |
Escherichia coli (EPEC) | L. casei | β-Intimin | Unknown | Serum IgG, mucosal IgM, challenge | Human | 77 |
Escherichia coli (ETEC) | L. casei | K88 | Unknown | Serum IgG, mucosal sIgA, challenge | Human | 128 |
Escherichia coli (ETEC) | L. casei | FaeG | Secreted | Stability | Human | 129 |
Escherichia coli (ETEC) | L. casei | FP | Secreted | Stability | Human | 129 |
Escherichia coli (ETEC) | L. casei | F1 | Surface | Serum IgG, mucosal IgA, challenge | Swine, ruminants, human |
75 |
Escherichia coli (ETEC) | L. casei | K88, K99 | Surface | Serum IgG, mucosal IgA, T cell response | Swine, ruminants, human |
74 |
Escherichia coli (ETEC) | L. casei | K99 | Surface | Serum IgG, mucosal IgA | Swine, ruminants, human |
73 |
Escherichia coli (ETEC) | L. casei | F41 | Surface | Serum IgG, mucosal IgA, T cell response | Swine, ruminants, human |
72 |
Escherichia coli (ETEC) | L. reuteri | ST, LT(B) | Secreted | Serum IgG, mucosal IgA, challenge protection |
Swine, ruminants, human |
76 |
Escherichia coli (ETEC) | L. acidophilus | K99 | Surface | In vitro inhibition of pathogen adhesion | Swine, ruminants, human |
130 |
Escherichia coli (ETEC) | L. plantarum | Fimbrial adhesin (FaeG) |
Unknown | Serum IgG, intestinal IgA, challenge | Swine, ruminant, human |
131 |
Escherichia coli (UPEC) | L. reuteri | PapG | Surface | Stability | Human | 132 |
Helicobacter pylori | L. acidophilus | Hp0410 | Unknown | Serum IgG, mucosal IgA, challenge | Human | 85 |
Helicobacter pylori | L. acidophilus | Hp0410 | Surface | Stability | Human | 133 |
Helicobacter pylori | L. plantarum | UreB | Unknown | Serum IgG, serum IgA, challenge | Human | 134 |
Mycobacterium avium (MAP) |
L. salivarius | MMP | Surface | Stability | Ruminant | 135 |
Mycobacterium avium (MAP) |
L. salivarius | ptD | Intracell. | Stability | Ruminant | 136 |
Mycobacterium tuberculosis | L. plantarum | Ag85B, ESAT-6 |
Surface | Mucosal IgA, T cell response | Human | 137 |
Salmonella enterica (SE) | L. casei | FliC, SipC | Surface | Serum IgG, T cell response | Human, animal |
138 |
Salmonella enterica (SE) | L. casei | FliC | Surface | Challenge | Human | 139 |
Streptococcus mutans | L. zeae | scFv | Surface, secreted |
Challenge | Human | 140 |
Streptococcus pneumoniae | L. casei | PspC | Surface, intracell. |
Mucosal IgA, challenge | Human | 141 |
Streptococcus pneumoniae | L. casei | PspA, PspC | Surface | Serum IgG, mucosal IgA | Human | 81 |
Streptococcus pneumoniae | L. casei | PspA | Surface | Serum IgG, challenge | Human | 80 |
Streptococcus pneumoniae |
L. casei, L. plantarum, L. helveticus |
PspA | Surface | Serum IgG, mucosal IgA, challenge | Human | 79 |
Streptococcus pneumoniae | L. casei | PsaA, PspA′1, PspA′3 |
Intracell., secreted |
Stability | Human | 142 |
Streptococcus pyogenes | L. gasseri | CRR6 | Unknown | Serum IgG, mucosal IgA, challenge | Human | 143 |
Streptococcus pyogenes |
L. sake, L. fermentum |
M6 | Secreted, surface |
Stability | Human | 144 |
V. cholerae |
L. casei, L. reuteri |
CTB | Intracell., secreted |
Serum IgG | Human | 145 |
Vibrio parahaemolyticus | L. rhamnosus | MAM-7 | Unknown | MAM-7 expression (reduced Lactobacillus ability to inhibit pathogen) |
Human | 146 |
Vibrio parahaemolyticus | L. rhamnosus | MAM-7 | Unknown | Stability | Human | 146 |
Yersinia pestis | L. plantarum | LcrV | Surface | Serum IgG, mucosal IgA, T cell response | Human | 84 |
Yersinia pseudotuberculosis | L. plantarum | D1-D5, D4-D5 | Surface | Stability | Human | 147 |
FHA, filamentous hemagglutinin adhesin; BoNT, clostridial botulinum neurotoxin; TTFC, tetanus toxin fragment C; FP, fusion protein; MMP, mucous membrane pemphigoid; intracell., intracellular; Neutr. Ab, neutralizing antibody.